Cai Haodong, Yang Li, Shen Kefeng, Zhang Wei, Xiong Jie, Zhang Meilan, Mao Xia, Wang Ying, Xiao Min
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China.
Oncol Lett. 2018 Feb;15(2):2491-2494. doi: 10.3892/ol.2017.7611. Epub 2017 Dec 13.
E14a3 breakpoint cluster region (BCR)/ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL) fusion transcript is rare in Philadelphia chromosome positive disease, particularly in acute lymphoblastic leukemia (ALL). Recently an e14a3 fusion transcript was detected by multiple laboratory examinations, and the patient was suffering from ALL. Except for the BCR/ABL fusion gene, in the present study the patient additionally had an IKAROS family zinc finger 1 deletion which, has been confirmed as a significant adverse prognosis factor. Following 2 rounds of chemotherapy, the patient presented cytological remission; however, the patient then relapsed 2 months later. They then received chimeric antigen receptor modified (CAR-modified) T-cell therapy and achieved complete remission. CAR-modified T-cell therapy is a powerful novel therapy which, exhibited great potential for treating refractory ALL, regardless of the existence and form of the BCR/ABL fusion transcript.
E14a3断裂簇区域（BCR）/原癌基因1、非受体酪氨酸激酶（ABL）融合转录本在费城染色体阳性疾病中较为罕见，尤其是在急性淋巴细胞白血病（ALL）中。最近，通过多次实验室检查检测到一种e14a3融合转录本，该患者患有ALL。除了BCR/ABL融合基因外，在本研究中，该患者还存在IKAROS家族锌指1缺失，这已被确认为一个重要的不良预后因素。经过两轮化疗后，患者出现细胞学缓解；然而，患者在两个月后复发。随后他们接受了嵌合抗原受体修饰（CAR修饰）的T细胞疗法并实现了完全缓解。CAR修饰的T细胞疗法是一种强大的新型疗法，无论BCR/ABL融合转录本的存在与否及形式如何，在治疗难治性ALL方面都显示出巨大潜力。
